Furor rages over FDA approval of controversial Alzheimer’s drug Aduhelm

In Congress, some Democrats are complaining concerning the worth of the brand new Alzheimer’s drug, made by the Massachusetts-based biotech large Biogen, and threatening congressional hearings. In an interview, Rep. Peter Welch (D-Vt.) referred to as the value “merciless,” noting that beneficiaries within the conventional Medicare program would face cost-sharing of greater than $11,000 a 12 months if they didn’t have supplemental insurance coverage protection. And Half B premiums might go up for everybody.

Source link